Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts

Journal of Immunology

Volumn 180, Issue 4, 2008, Pages 2214-2224

  Jindra, Peter T ^a   Hsueh, Aileen ^a   Hong, Longshen ^a   Gjertson, David ^a   Shen, Xiu Da ^b   Gao, Feng ^b   Dang, Julie ^a   Mischel, Paul S ^a   Baldwin III, William M ^c   Fishbein, Michael C ^a   Kupiec Weglinski, Jerzy W ^b   Reed, Elaine F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 ANTIBODY; ANTIBODY; COMPLEMENT COMPONENT C4D; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAG1 PROTEIN; S6 KINASE; UNCLASSIFIED DRUG; ALLOANTIBODY; H 2K(K) ANTIGEN; H 2KB PROTEIN, MOUSE; H-2K(K) ANTIGEN; H-2KB PROTEIN, MOUSE; H2 ANTIGEN; HISTOCOMPATIBILITY ANTIGEN H 2D(B); HISTOCOMPATIBILITY ANTIGEN H-2D(B); MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BAGG ALBINO MOUSE; CARDIAC GRAFT REJECTION; CELL ACTIVATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME ACTIVATION; HEART TRANSPLANTATION; HETEROTOPIC TRANSPLANTATION; IN VIVO STUDY; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEOMICS; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; ENZYMOLOGY; GENETICS; GRAFT REJECTION; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PASSIVE IMMUNIZATION; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL PROLIFERATION; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GRAFT REJECTION; H-2 ANTIGENS; HEART TRANSPLANTATION; IMMUNIZATION, PASSIVE; ISOANTIBODIES; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 40849127258     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.4.2214     Document Type: Article

References (62)

1. Michaels, P. J., M. L. Espejo, J. Kobashigawa, J. C. Alejos, C. Burch, S. Takemoto, E. F. Reed, and M. C. Fishbein. 2003. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J. Heart Lung Transplant. 22: 58-69.
2. Reed, E. F., A. J. Demetris, E. Hammond, S. Itescu, J. A. Kobashigawa, N. L. Reinsmoen, E. R. Rodriguez, M. Rose, S. Stewart, N. Suciu-Foca, et al. 2006. Acute antibody-mediated rejection of cardiac transplants. J. Heart Lung Transplant. 25: 153-159.
3. Rodriguez, E. R., D. V. Skojec, C. D. Tan, A. A. Zachary, E. K. Kasper, J. V. Conte, and W. M. Baldwin, 3rd. 2005. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am. J. Transplant. 5: 2778-2785.
4. L and alloantibody. Am. J. Transplant. 1: 260-269.
5. Lin, Y., M. P. Soares, K. Sato, K. Takigami, E. Csizmadia, N. Smith, and F. H. Bach. 1999. Accommodated xenografts survive in the presence of anti-donor antibodies and complement that precipitate rejection of naive xenografts. J. Immunol. 163: 2850-2857.
6. Bach, F. H., C. Ferran, P. Hechenleitner, W. Mark, N. Koyamada, T. Miyatake, H. Winkler, A. Badrichani, D. Candinas, and W. W. Hancock. 1997. Accommodation of vascularized xenografts: expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environment. Nat. Med. 3: 196-204.
7. Platt, J. L. 1994. A perspective on xenograft rejection and accommodation. Immunol. Rev. 141: 127-149.
8. Williams, J. M., Z. E. Holzknecht, T. B. Plummer, S. S. Lin, G. J. Brunn, and J. L. Platt. 2004. Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation. Transplantation 78: 1471-1478.
9. Bian, H., and E. F. Reed. 2001. Anti-HLA class I antibodies transduce signals in endothelial cells resulting in FGF receptor translocation, down-regulation of ICAM-1 and cell proliferation. Transplant. Proc. 33: 311.
10. Jin, Y. P., P. T. Jindra, K. W. Gong, E. J. Lepin, and E. F. Reed. 2005. Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplantation 79: S19-S21.
11. Narayanan, K., A. Jaramillo, D. L. Phelan, and T. Mohanakumar. 2004. Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur. J. Immunol. 34: 2303-2312.
12. Lepin, E. J., Y. P. Jin, S. P. Barwe, E. Rozengurt, and E. F. Reed. 2004. HLA class I signal transduction is dependent on Rho GTPase and ROK. Biochem. Biophys. Res. Commun. 323: 213-217.
13. Narayanan, K., M. D. Jendrisak, D. L. Phelan, and T. Mohanakumar. 2006. HLA class I antibody mediated accommodation of endothelial cells via the activation of PI3K/cAMP dependent PKA pathway. Transpl. Immunol. 15: 187-197.
14. Jin, Y. P., R. P. Singh, Z. Y. Du, A. K. Rajasekaran, E. Rozengurt, and E. F. Reed. 2002. Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent manner. J. Immunol. 168: 5415-5423.
15. L expression in endothelial cells. Hum. Immunol. 65: 291-302.
16. Jindra, P. T., X. Zhang, A. Mulder, F. Claas, J. Veale, Y. P. Jin, and E. F. Reed. 2006. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation 82: S33-S35.
17. Lepin, E. J., Q. Zhang, X. Zhang, P. T. Jindra, L. S. Hong, P. Ayele, M. V. Peralta, D. W. Gjertson, J. A. Kobashigawa, W. D. Wallace, et al. 2006. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am. J. Transplant. 6: 1560-1571.
18. Russell, P. S., C. M. Chase, and R. B. Colvin. 1997. Alloantibody- and T cel-lmediated immunity in the pathogenesis of transplant arteriosclerosis: lack of progression to sclerotic lesions in B cell-deficient mice. Transplantation 64: 1531-1536.
19. Wasowska, B. A., Z. Qian, D. L. Cangello, E. Behrens, K. Van Tran, J. Layton, F. Sanfilippo, and W. M. Baldwin, 3rd. 2001. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation 71: 727-736.
20. Brandle, D., J. Joergensen, G. Zenke, K. Burki, and R. P. Hof. 1998. Contribution of donor-specific antibodies to acute allograft rejection: evidence from B cell-deficient mice. Transplantation 65: 1489-1493.
21. Shi, C., W. S. Lee, Q. He, D. Zhang, D. L. Fletcher, Jr., J. B. Newell, and E. Haber. 1996. Immunologic basis of transplant-associated arteriosclerosis. Proc. Natl. Acad. Sci. USA 93: 4051-4056.
22. Shi, C., M. E. Russell, C. Bianchi, J. B. Newell, and E. Haber. 1994. Murine model of accelerated transplant arteriosclerosis. Circ. Res. 75: 199-207.
23. Stewart, S., G. L. Winters, M. C. Fishbein, H. D. Tazelaar, J. Kobashigawa, J. Abrams, C. B. Andersen, A. Angelini, G. J. Berry, M. M. Burke, et al. 2005. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J. Heart Lung Transplant. 24: 1710-1720.
24. Corry, R. J., H. J. Winn, and P. S. Russell. 1973. Primarily vascularized allografts of hearts in mice: the role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 16: 343-350.
25. Bian, H., P. E. Harris, and E. F. Reed. 1998. Ligation of HLA class I molecules on smooth muscle cells with anti-HLA antibodies induces tyrosine phosphorylation, fibroblast growth factor receptor expression and cell proliferation. Int. Immunol. 10: 1315-1323.
26. Lones, M. A., L. S. Czer, A. Trento, D. Harasty, J. M. Miller, and M. C. Fishbein. 1995. Clinical-pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients. J. Heart Lung Transplant. 14: 151-162.
27. Murata, K., K. Fox-Talbot, Z. Qian, K. Takahashi, G. L. Stahl, W. M. Baldwin, 3rd, and B. A. Wasowska. 2007. Synergistic deposition of C4d by complement-activating and non-activating antibodies in cardiac transplants. Am. J. Transplant. 7: 2605-2614.
28. Minami, K., K. Murata, C. Y. Lee, K. Fox-Talbot, B. A. Wasowska, M. D. Pescovitz, and W. M. Baldwin, 3rd. 2006. C4d deposition and clearance in cardiac transplants correlates with alloantibody levels and rejection in rats. Am. J. Transplant. 6: 923-932.
29. Regele, H., M. Exner, B. Watschinger, C. Wenter, M. Wahrmann, C. Osterreicher, M. D. Saemann, N. Mersich, W. H. Horl, G. J. Zlabinger, and G. A. Bohmig. 2001. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol. Dial. Transplant. 16: 2058-2066.
30. Choe, G., S. Horvath, T. F. Cloughesy, K. Crosby, D. Seligson, A. Palotie, L. Inge, B. L. Smith, C. L. Sawyers, and P. S. Mischel. 2003. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63: 2742-2746.
31. Wasowska, B. A., Z. Qian, D. L. Cangello, K. Van Tran, J. L. Layton, F. Sanfilippo, and W. M. Baldwin, 3rd. 2001. Alloantibodies restore cardiac allograft rejection to IgKO mice. Transplant. Proc. 33: 317.
32. Fuller, T. C., and H. J. Winn. 1973. Immunochemical and biologic characterization of alloantibody active in immunologic enhancement. Transplant. Proc. 5: 585-587.
33. Uehara, S., C. M. Chase, L. D. Cornell, J. C. Madsen, P. S. Russell, and R. B. Colvin. 2007. Chronic cardiac transplant arteriopathy in mice: relationship of alloantibody, C4d deposition and neointimal fibrosis. Am. J. Transplant. 7: 57-65.
34. Reed, E. F. 2003. Signal transduction via MHC class I molecules in endothelial and smooth muscle cells. Crit. Rev. Immunol. 23: 109-128.
35. Kacskovics, I., Z. Kis, B. Mayer, A. P. West, Jr., N. E. Tiangco, M. Tilahun, L. Cervenak, P. J. Bjorkman, R. A. Goldsby, O. Szenci, and L. Hammarstrom. 2006. FcRn mediates elongated serum half-life of human IgG in cattle. Int. Immunol. 18: 525-536.
36. Akilesh, S., G. J. Christianson, D. C. Roopenian, and A. S. Shaw. 2007. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J. Immunol. 179: 4580-4588.
37. Roopenian, D. C., and S. Akilesh. 2007. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7: 715-725.
38. Borvak, J., J. Richardson, C. Medesan, F. Antohe, C. Radu, M. Simionescu, V. Ghetie, and E. S. Ward. 1998. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int. Immunol. 10: 1289-1298.
39. Jenkins, S. L., J. Wang, M. Vazir, J. Vela, O. Sahagun, P. Gabbay, L. Hoang, R. L. Diaz, R. Aranda, and M. G. Martin. 2003. Role of passive and adaptive immunity in influencing enterocyte-specific gene expression. Am. J. Physiol. 285: G714-G725.
40. Kim, D. H., D. D. Sarbassov, S. M. Ali, J. E. King, R. R. Latek, H. Erdjument-Bromage, P. Tempst, and D. M. Sabatini. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175.
41. Nojima, H., C. Tokunaga, S. Eguchi, N. Oshiro, S. Hidayat, K. Yoshino, K. Hara, N. Tanaka, J. Avruch, and K. Yonezawa. 2003. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. 278: 15461-15464.
42. Hara, K., Y. Maruki, X. Long, K. Yoshino, N. Oshiro, S. Hidayat, C. Tokunaga, J. Avruch, and K. Yonezawa. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177-189.
43. Hay, N., and N. Sonenberg. 2004. Upstream and downstream of mTOR. Genes Dev. 18: 1926-1945.
44. Hidalgo, M., and E. K. Rowinsky. 2000. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680-6686.
45. Murakami, M., T. Ichisaka, M. Maeda, N. Oshiro, K. Hara, F. Edenhofer, H. Kiyama, K. Yonezawa, and S. Yamanaka. 2004. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell. Biol. 24: 6710-6718.
46. Gangloff, Y. G., M. Mueller, S. G. Dann, P. Svoboda, M. Sticker, J. F. Spetz, S. H. Um, E. J. Brown, S. Cereghini, G. Thomas, and S. C. Kozma. 2004. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell. Biol. 24: 9508-9516.
47. Guertin, D. A., D. M. Stevens, C. C. Thoreen, A. A. Burds, N. Y. Kalaany, J. Moffat, M. Brown, K. J. Fitzgerald, and D. M. Sabatini. 2006. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1. Dev. Cell 11: 859-871.
48. Holzknecht, Z. E., K. L. Kuypers, T. B. Plummer, J. Williams, M. Bustos, G. J. Gores, G. J. Brunn, and J. L. Platt. 2002. Apoptosis and cellular activation in the pathogenesis of acute vascular rejection. Circ. Res. 91: 1135-1141.
49. Kotenko, S. V., S. Saccani, L. S. Izotova, O. V. Mirochnitchenko, and S. Pestka. 2000. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc. Natl. Acad. Sci. USA 97: 1695-1700.
50. Pinney, S. P., and D. Mancini. 2004. Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment. Curr. Opin. Cardiol. 19: 170-176.
51. Schaller, M. D. 2001. Paxillin: a focal adhesion-associated adaptor protein. Oncogene 20: 6459-6472.
52. Mitra, S. K., D. A. Hanson, and D. D. Schlaepfer. 2005. Focal adhesion kinase: in command and control of cell motility. Nat. Rev. Mol. Cell Biol. 6: 56-68.
53. Holz, M. K., and J. Blenis. 2005. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J. Biol. Chem. 280: 26089-26093.
54. Sarbassov, D. D., D. A. Guertin, S. M. Ali, and D. M. Sabatini. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
55. Yang, Q., K. Inoki, T. Ikenoue, and K. L. Guan. 2006. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 20: 2820-2832.
56. Dormond, O., J. C. Madsen, and D. M. Briscoe. 2007. The effects of mTOR-AKT interactions on anti-apoptotic signaling in vascular endothelial cells. J. Biol. Chem. 282: 23679-23686.
57. Rahimi, S., Z. Qian, J. Layton, K. Fox-Talbot, W. M. Baldwin, 3rd, and B. A. Wasowska. 2004. Non-complement- and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am. J. Transplant. 4: 326-334.
58. Larsen, T. H., J. E. Hesketh, S. Rotevatn, G. Greve, and T. Saetersdal. 1994. Ribosome distribution in normal and infarcted rat hearts. Histochem. J. 26: 79-89.
59. Haas, M., M. H. Rahman, L. C. Racusen, E. S. Kraus, S. M. Bagnasco, D. L. Segev, C. E. Simpkins, D. S. Warren, K. E. King, A. A. Zachary, and R. A. Montgomery. 2006. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am. J. Transplant. 6: 1829-1840.
60. Ionescu, D. N., A. L. Girnita, A. Zeevi, R. Duquesnoy, J. Pilewski, B. Johnson, S. Studer, K. R. McCurry, and S. A. Yousem. 2005. C4d deposition in lung allografts is associated with circulating anti-HLA alloantibody. Transpl. Immunol. 15: 63-68.
61. Collins, A. B., E. E. Schneeberger, M. A. Pascual, S. L. Saidman, W. W. Williams, N. Tolkoff-Rubin, A. B. Cosimi, and R. B. Colvin. 1999. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J. Am. Soc. Nephrol. 10: 2208-2214.
62. Feucht, H. E. 2003. Complement C4d in graft capillaries-the missing link in the recognition of humoral alloreactivity. Am. J. Transplant. 3: 646-652.